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Abstract
Background: Smoking history is often di- or trichotomized into for example "never, ever or
current smoking". However, smoking must be treated as a time-dependent covariate when lifetime
data is available. In particular, individuals do not smoke at birth, there is usually a wide variation
with respect to smoking history, and smoking cessation must also be considered.
Methods: Therefore we analyzed smoking as a time-dependent risk factor for cardiovascular
atherosclerotic events in a cohort of 2400 individuals with familial hypercholesterolemia who were
followed from birth until 2004. Excess risk after smoking-cessation was modelled in a Cox
regression model with linear and exponential decaying trends. The model with the highest
likelihood value was used to estimate the decay of the excess risk of smoking.
Results: Atherosclerotic events were observed in 779 patients with familial hypercholesterolemia
and 1569 individuals had a smoking history. In the model with the highest likelihood value the risk
reduction of smoking after cessation follows a linear pattern with time and it appears to take 6 to
9 years before the excess risk is reduced to zero. The risk of atherosclerotic events due to smoking
was estimated as 2.1 (95% confidence interval 1.5; 2.9).
Conclusion: It was concluded that excess risk due to smoking declined linearly after cessation in
at least six to nine years.
Background
Smoking is one of the most important risk factors for dis-
ease, particularly for lung, and cardiovascular disease
(CVD) [1]. In many studies where lifetime smoking data
is not available, a patient's smoking history is dichot-
omized into "yes or no smoking", or trichotomized into
"never, ever, or current smoking". Subsequently, odds
ratios or relative risks are calculated in a case-control study
or cohort study, respectively. Although likely crude, the
untoward effect of smoking is clearly illustrated in such
Published: 23 October 2006
BMC Public Health 2006, 6:262 doi:10.1186/1471-2458-6-262
Received: 14 February 2006
Accepted: 23 October 2006
This article is available from: http://www.biomedcentral.com/1471-2458/6/262
© 2006 Kramer et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Page 1 of 7
(page number not for citation purposes)
BMC Public Health 2006, 6:262 http://www.biomedcentral.com/1471-2458/6/262analyses, provided that smoking occurred before develop-
ment of disease in the case-control study, or that follow-
up in the cohort study started at some point in time at
which smoking history could be determined. Many prog-
nostic models have been developed with smoking as a
time-independent factor, i.e. not changing in time. Exam-
ples of such models for cardiovascular disease are the
Framingham risk score [2], the Procam risk score [3], and
recently the score developed by Yusuf et al. [1]. It is chal-
lenging to collect reliable data on smoking from decades
ago, and this may be the reason why di- or trichotomiza-
tion, is often used to summarize smoking history. But this
is often suboptimal since it is likely that a person who
ceased smoking ten years ago is at a different risk for
developing cardiovascular disease, for instance, than a
person who ceased smoking at the day follow-up started
in a cohort study.
When lifetime risk data are available, the di- or trichot-
omization of smoking history is not appropriate, because
follow-up starts at birth. This report evaluates the develop-
ment of cardiovascular disease in individuals with Famil-
ial Hypercholesterolemia (FH) [4], and the use of
smoking as a time-dependent variable in this study
(GIRaFH study). These individuals have a mutation of the
low density lipoprotein (LDL)-receptor gene which causes
severely increased LDL-cholesterol levels from birth
onwards, and therefore an increased risk of CVD. In this
study, FH-individuals were followed from birth and all
cardiovascular events were registered. The aim was to
quantify the lifetime risk and the influence of classical risk
factors, such as smoking, for cardiovascular disease [4]. In
this study smoking could not be treated as a time-inde-
pendent risk factor since individuals did not smoke at
birth, and because there was very large variation with
respect to the age at which smoking started, and age of
smoking cessation. In the statistical analysis of such data,
smoking is commonly treated as a time-dependent varia-
ble. Its value is set to zero at birth, and then changes to
unity at the age at which the individual starts smoking.
When the individual stops smoking, the value may be
changed back to zero, which implies that the excess risk
due to smoking reduces to zero immediately upon cessa-
tion. Alternatively, the value of the time-dependent varia-
ble may be kept at unity for the remaining lifetime, which
implies that the excess risk of smoking remains even after
cessation. The best choice is likely in between, implying
that the excess risk due to smoking decreases gradually
after cessation. Dobson and co-workers [5,6] performed
two case-control studies in individuals with coronary
artery disease, and found that the excess risk of smoking
disappeared 3 to 6 years after smoking cessation. The
present study analyzes the risk of cardiovascular athero-
sclerotic events as a function of smoking and time since
smoking cessation in a cohort of 2400 individuals with
FH who were followed from birth onwards.
Methods
Study design and study population
The GIRaFH study was a retrospective, multicenter, cohort
study. The study design and study population have been
described elsewhere [4]. Briefly, lipid clinics in the Neth-
erlands submit DNA samples from clinically suspected FH
patients to a central laboratory for LDL-receptor mutation
analysis [7]. We randomly selected hypercholesterolemic
patients from this DNA-bank database. These patients had
been referred from 27 lipid clinics throughout the Nether-
lands. A total of 2400 FH patients were included in this
study. The FH diagnostic criteria were based on interna-
tionally established criteria [8].
Phenotypic data (including detailed information on car-
diovascular events) were acquired by reviewing patient's
medical records by a trained team of data collectors [9].
Guidelines for data collection from medical records were
constructed for the purpose of the study and have been
published [9]. Written informed consent was obtained
from all living patients. The Ethics Institutional Review
Board of each participating hospital approved the proto-
col.
Determination of smoking-history
Upon review of the patient's medical records, sufficient
data on lifetime smoking status was available in the med-
ical records of 68 percent of the patients. Questionnaires
were mailed to all participants in order to supplement the
smoking data. In addition to the number of cigarettes
smoked per day, the questionnaire contained questions
on age when the person started smoking, age(s) when
smoking cessation was attempted, and age of final cessa-
tion. With the supplemental data collected from the ques-
tionnaires, lifetime smoking status could be reconstructed
in 88 percent of the patients. Temporary cessations were
exceptional and short, and we decided to analyze final
cessation dates only. Patients of whom smoking status
was unknown, had slightly higher HDL levels (1.33 vs
1.23 mmol/L, p = 0.001), and they had lower triglyceride
levels (1.68 vs 1.92 mmol/L, p = 0.009). On the other cov-
ariates that we analyze in this paper the two patient
groups were not significantly different.
Other risk factors
Male gender, smoking, body mass index and the presence
of hypertension, and diabetes mellitus were considered
classical risk factors. Hypertension was defined when the
diagnosis had been made and when anti-hypertensive
medication was prescribed, or if three consecutive blood
pressure measurements were > 140 mmHg systolic or > 90
mmHg diastolic. Diabetes mellitus was defined when thePage 2 of 7
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anti-diabetics) was prescribed, or by a fasting glucose of >
6.9 mmol/L. In the statistical analysis, both hypertension
and diabetes mellitus were handled as binary covariates
depending on age; before age of diagnosis the risk factor
was considered to be absent, and after diagnosis it was
considered present for the remaining life.
All laboratory parameters were measured in fasting blood
samples after at least 6 weeks of withdrawal of any lipid-
lowering medication. The presented values are those from
as close to the first lipid clinic visit as possible, with a max-
imum time-span of two years. Plasma total cholesterol,
high density lipoprotein (HDL) cholesterol, and triglycer-
ides were measured by standard enzymatic methods. Low
density lipoprotein (LDL) cholesterol concentrations
were calculated by means of the Friedewald formula.
Apolipoprotein (a) (Lp(a)) was measured with immu-
nonephelometric methods. Plasma homocysteine was
measured by high-performance liquid chromatography.
These laboratory parameters were handled as time-inde-
pendent covariates in the statistical analysis.
Definition of atherosclerotic events
In this study the primary outcomes were cardiovascular
mortality and non-fatal cardiovascular events. Cardiovas-
cular events were defined as (I) acute myocardial infarc-
tion (AMI), proven by at least two of the following: (a)
classical symptoms (> 15 minutes), (b) specific EKG
abnormalities, (c) elevated cardiac enzymes (> 2x upper
limit of normal); (II) percutaneous coronary intervention
(PCI) or other invasive procedures; (III) coronary artery
bypass grafting (CABG); (IV) angina pectoris (AP), diag-
nosed as classical symptoms in combination with at least
one unequivocal result of one of the following; (a) exer-
cise test, (b) nuclear scintigram, (c) dobutamine stress
ultrasound, (d) a more than 70 percent stenosis on a cor-
onary angiogram; (V) ischemic stroke, demonstrated by
CT- or MRI scan; (VI) documented transient ischemic
attack (TIA); (VII) peripheral arterial bypass graft (PBG);
(VIII) peripheral percutaneous transluminal angioplasty
(PTA) or other percutaneous invasive intervention; (IX)
intermittent claudication defined as classical symptoms in
combination with at least one equivocal result of one of
the following: (a) ankle/arm index < 0.9 or (b) a stenosis
(> 50 percent) on an angiogram or duplex scan. If infor-
mation on cardiovascular events did not strictly fulfill the
above-mentioned criteria, or if any suspect history, symp-
toms, or diagnostic evaluations were found in the medical
record, the case was presented to an independent adjudi-
cation committee [9].
Statistical analysis
We consider the risk, subsequently denoted as hazard, of
first (atherosclerotic) event as a function of age: h(t) rep-
resents the hazard at age t. Suppose that person i started
smoking at age a0 and ceased smoking at age a1. In this
paper we will use the proportional hazards (or Cox)
model and we model the hazard of an event in person i as
follows:
• if t <a0 then h(t|i) = h0(t);
• if a0 ≤ t <a1 then h(t|i) = h0(t) * exp(β);
• if t ≥ a1 then h(t|i) = h0(t) * exp(γ(t, a1)),
where h0(t) is the baseline hazard-function, β is the log-
hazard ratio due to smoking in the age-period when per-
son i smoked, and γ(t, a1) is the log-hazard ratio at age t
due to smoking-cessation at age a1 (t > a1). Simple choices
for γ(t, a1) are (i) γ(t, a1) = β, or (ii) γ(t, a1) = 0. In many
cases it is likely that the excess-risk due to smoking only
gradually disappears, for instance as a linear function (iii)
γ(t, a1) = β(1 - δ * (t - a1)) or as an exponential function
(iv) γ(t, a1) = β * exp(-p * (t - a1)), where δ and p are
(unknown) parameters determining the speed of decrease
of excess-risk after smoking-cessation. δ is a slope param-
eter and a0 + 1/δ defines age after which the excess risk of
smoking equals zero. There are an infinite number of
monotonic decreasing functions, but most can be approx-
imated very well by the linear or exponential models.
Models (i) and (ii) are special cases of a proportional haz-
ards or Cox model with a simple time-dependent covari-
ate, and the unknown parameter β can be easily estimated
using standard algorithms. Models (iii) and (iv) can be re-
written such that they also conform to the proportional
hazards model, and the unknown parameters β, δ, and p
can be estimated using standard algorithms for the pro-
portional hazards model. To that end the time-dependent
covariate xit was introduced, which is equal to zero if t <a0,
equals unity if a0 ≤ t <a1, and equals exp(-p * (t - a1)) in the
exponential model if t ≥ a1. For the linear decreasing
model xit equals (1 - δ * (t - a1)) if t > a1 (and xit ≥ 0).
The hazard function can be therefore written as h(t|i) =
h0(t) * exp(β * xit), which is a standard proportional haz-
ards model with a time-dependent covariate if p or δ is
known. Since p and δ are unknown a two-step estimation
procedure was used in which p or δ was varied along a
grid, and for each value of p or δ we estimated β using the
standard algorithms (using the partial likelihood). The
value of p or δ with the highest likelihood value was then
finally selected. The advantage of this two-step approach
was that existing software programs like SAS, SPSS, or
STATA could be used. Disadvantageous of this procedure
was that the unreliability of the estimates of p and δ were
not automatically incorporated in the standard error of
the estimate of β. To incorporate that uncertainty in thePage 3 of 7
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bootstrap procedure; in each bootstrap sample we deter-
mined optimal values of p or δ as well as the associated
partial likelihood estimated of β. Standard error of β was
subsequently derived from the distribution of the esti-
mates in the bootstrap samples [10].
In the Cox model we always included as covariates gender,
LDL-cholesterol, HDL-cholesterol, triglyceride level,
homocysteine, and Lp(a) and hypertension, and diabetes
mellitus as age-dependent variables.
Results and discussion
Cardiovascular events were observed in 779 of the 2400
individuals included in this study. Most (n = 661) were
cardiac in origin (306 Acute Myocardial Infarction, 11
Percutaneous Coronary Intervention, 19 Coronary Artery
Bypass Grafting, 325 Angina Pectoris). There were 53
patients with cerebrovascular incidents (24 stroke, 29
Transient Ischemic Attack), 69 with peripheral vascular
incidents (13 Peripheral Bypass Grafting/Percutanoeus
Transient Angioplasty, 56 Claudicatio Intermittens), and
two patients died without prior atherosclerotic events. Age
of first event varied between 18 and 85 years of age with
median 46.2 years. In the individuals without events, age
varied between 18 and 86 with median 45.6. Cumulative
incidences at thirty, forty, fifty, sixty, and seventy years of
age were 0.9%, 8.8%, 25.9%, 47.6%, and 66.5%, respec-
tively. Univariate hazard ratios of the risk factors used in
this analysis are presented in Table 1; all were statistically
significant.
Cardiovascular disease was increased in smokers com-
pared to non-smokers, and this risk decreased after cessa-
tion. To illustrate this, the hazard was calculated for events
in persons who ceased smoking in yearly intervals since
age of smoking cessation. These hazards were compared
with those in a group of individuals of comparable age
who never smoked (average age of smoking cessation was
43.2 years). These hazards are given in Figure 1, and the
risk is clearly increased in ex-smokers at least in the first
five years after cessation. The comparison is, however,
uncontrolled for other risk factors.
The estimated rates of decline per year in excess risk after
smoking-cessation according to a linear model (iii:
parameter δ), or to an exponential model (iv: parameter
p) are given in Table 2, together with the log hazard ratio
af events due to smoking (β). Lowest deviance values (-
2*loglikelihood) of the linear and exponential models
were found for  = 0.11 and  = 0.095. Both models had
much lower deviance than the models (i) with constant
remaining excess risk or (ii) with no excess risk after cessa-
tion. The linear model at the optimal value of the slope
parameter (  = 0.11) had slightly lower deviance than
the exponential model, but the difference was small. Devi-
ance values differed only slightly along a large range of
values of δ or p, indicating that these parameters were dif-
ficult to identify despite the large number of patients, the
large number of events, and the large number of exposed
individuals: see Figures 2a and 2b. The excess-risk five or
more years after cessation was especially uncertain,
because the linear and exponential decreasing models had
a similar pattern up to about five years after cessation, but
diverged afterwards (see Figure 3). Some idea about the
uncertainty of  or  can be obtained from Figure 2, but
this uncertainty was not incorporated in the estimators of
the standard errors of  in Table 2. To evaluate this effect
1000 bootstrap samples were drawn from the cohort of
2400 patients, and δ, and β were estimated in each boot-
strap sample. The bootstrap standard deviation was only
slightly larger than the maximum partial loglikelihood






Table 1: Demographic and biochemical characteristics of the patients in the database and univariate hazard ratio for first 
atherosclerotic event
Risk factor value Univariate HR (95% CI)
Gender (% men) 49.2 2.95 (2.54; 3.43)
Hypertension1 (%) 10.0 1.44 (1.17; 1.78)
Diabetes Mellitus1 (%) 5.8 2.38 (1.49; 3.83)
LDL-C (mmol/L): mean (SD) 6.58 (1.86) 0.95 (0.91; 0.99)
HDL-C (mmol/L): mean (SD) 1.23 (0.35) 0.32 (0.26; 0.41)
Triglycerides (mmol/L): mean (SD) 1.70 (1.02) 1.14 (1.07; 1.22)
Homocysteine (μmol/L): mean (SD) 12.4 (8.9) 1.08 (1.04; 1.11)2
Lp(a) (mg/L): mean (SD) 338 (419) 1.04 (1.02; 1.06)3
1 Hypertension and Diabetes Mellitus were analyzed as time-dependent covariates. 2 Hazard-ratio per 5 μmol/L increase Homocysteine. 3 Hazard-
ratio per 100 mg/L increase Lp(a). HDL-c = high density lipoprotein cholesterol; LDL-C = low density lipoprotein cholesterol; Lp(a) = 
apolipoprotein(a); HR = hazard ratio.Page 4 of 7
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the hazard ratio (HR) of smoking was estimated as 2.01
with 95% confidence interval (CI) 1.72; 2.34. After con-
trolling for the risk-factors in Table 1 the smoking hazard
ratio was 2.02 (95% CI: 1.44; 2.84). The optimal value for
δ was estimated in the multivariable model as  = 0.18,
and the estimated smoking hazard ratio at that δ-value
was slightly larger: 2.06 (95% CI: 1.47; 2.87).
Conclusion
Smoking cessation in individuals with Familial Hypercho-
lesterolemia was associated with considerable decrease of
the risk of cardiovascular atherosclerotic events. The risk
reduction proved to follow a linear pattern over time, but
it was difficult to distinguish this from nonlinear patterns.
The slope of the linear reduction-line was estimated as
0.11 univariately, and 0.18 when corrected for confound-
ers. This means that it took 1/0.18 ≈ 6 to 1/0.11 ≈ 9 years
δˆ
δˆ
Deviance (-2 * Partial loglikelihood) values as a function of th  parameters δ or p in th  m dels with line rly or exp -nenti lly d creasing risk aft r smoking-c s tionFigure 2
Deviance (-2 * Partial loglikelihood) values as a func-
tion of the parameters δ or p in the models with line-
arly or exponentially decreasing risk after smoking-
cessation. Deviance values for the models with linear and 
exponential decreasing hazard after smoking-cessation as a 
function of the regression parameters in both models (δ and 
p).




















Observed hazard for cardiovascular mortality/events in ex-smokers and in non-smokersFigure 1
Observed hazard for cardiovascular mortality/events 
in ex-smokers and in non-smokers. Proportion of events 
per year since smoking cessation in persons who ceased 
smoking compared with a group of individuals of comparable 
age who never smoked.
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Table 2: Deviance, and smoking log-hazard ratio (HR) plus 
standard error (SE) in the different models
model deviance log(HR) (SE)
(i) constant excess risk 10455.93 0.643 (0.083)
(ii) no excess risk 10542.84 0.188 (0.075)
(iii) linearly decreasing 
risk
δ = 0 10455.93 0.643 (0.083)
δ = 0.05 10441.41 0.718 (0.082)
δ = 0.09 10438.31 0.708 (0.079)
δ = 0.10 10438.26 0.705 (0.079)
δ = 0.11 10438.09 0.704 (0.077)
δ = 0.15 10438.56 0.689 (0.077)
δ = 0.20 10439.79 0.672 (0.077)
δ = 0.25 10444.98 0.660 (0.076)
(iv) exponentially 
decreasing risk
p = 0 10455.93 0.643 (0.083)
p = 0.05 10439.82 0.758 (0.087)
p = 0.09 10438.57 0.743 (0.084)
p = 0.095 10438.56 0.741 (0.083)
p = 0.10 10438.58 0.738 (0.083)
p = 0.125 10438.84 0.728 (0.082)
p = 0.15 10439.33 0.719 (0.081)
p = 0.3 10443.87 0.678 (0.078)
All p-values < 0.001, except for model (ii) p = 0.012. Standard errors 
were calculated using δ and p as given constants.Page 5 of 7
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persons who never smoked.
The risk of atherosclerotic events due to smoking was esti-
mated at 2.1 (95% ci: 1.5; 2.9), which coincides with
many results in the literature [11-13], or only slightly
higher [14-16]. We found only weak relationships
between atherosclerotic events and number of cigarettes
smoked, but this is probably due to the unreliability of
these data (20 percent of the patients were not willing or
able to quantify the number cigarettes smoked).
The estimate that it takes six to nine years after smoking
cessation before the risk of atherosclerotic events is
reduced to the level of persons who never smoked, agrees
with findings by others. McElduff et al [6] found that the
excess risk for a major coronary event due to smoking dis-
appeared about four to six years after smoking-cessation
in a population-based case-control study of 5,572 cases
and 6,268 controls. Wannamethee et al [11] observed a
similar stroke-risk reduction in 7,735 middle aged men,
although the speed of reduction depended on smoking-
quantity. In a population-based cohort of 758 women,
Witteman et al [12] found that the excess risk for calcific
deposits in the abdominal aorta was increased up to 10
years after cessation. Negri et al [13] also observed that it
took up to 10 years after cessation before risk of acute
myocardial infarction was reduced to the level of never-
smokers in 916 cases with acute myocardial infarction
and 1106 controls. A slightly longer period was observed
by Kawachi et al [17] in the Nurses' Health Study among
117,001 nurses; they found that the risk of total coronary
heart disease reduced by one third within 2 years of cessa-
tion, but afterwards it took 10 to 14 years for this excess
risk to return to the level of those who never smoked.
Chaturvedi et al [18] also observed a longer period (> 10
years) for the excess mortality-risk returned to normal in
4,427 individuals with diabetes. Omenn et al [19]
observed that this excess risk was increased up to 20 years
after cessation in 21,112 men and women evaluated with
coronary angiography. A far shorter period of three years
was found, however, by Rea et al [14] in a cohort of 2,169
persons who survived after first myocardial infarction. The
variation in speed of risk-reduction after cessation
between all these studies is probably caused by the differ-
ences in populations. In our population of familial hyper-
cholesterolemia atherosclerosis is known to develop
earlier in live with an increased speed of progression. It is
possible that exposure to smoking has a bigger impact,
and therefor takes longer to diminish. But next to differ-
ences in populations between the above mentioned stud-
ies, the variation is, in our view, also illustration of the
difficulty to estimate the pattern with which excess risk
reduces after cessation. Moreover, the lifetime smoking
history was reconstructed from retrospective review of
medical records and patient recall -both are known to be
of poor quality-, and this will also influence outcome of
our study.
We used the Cox regression model with smoking as a
time-dependent covariate for statistical analysis of the risk
after smoking-cessation. The time dependence of the
excess-risk after smoking-cessation was modelled with a
linear or exponential decaying trend; these two models
were very flexible and capable of many possible patterns,
but even more flexibility may be obtained with nonpara-
metric techniques such as splines, kernels functions or
lowess regression. We doubt whether such techniques
offer much more insight because we found that it was
already very difficult to distinguish different linear and
(parametric) nonlinear patterns; even more irregular pat-
terns will be even harder to distinguish. Others [14,15]
used data-driven methods to estimate the excess-risk in ex-
smokers in one, two, three, and up to ten years after cessa-
tion. Such statistical modelling is nonparametric in a way,
since no assumption is made on the way the risk reduces
after smoking-cessation, but this approach requires more
parameters to be estimated, and therefore introduces
more uncertainty.
We used a bootstrap approach to account for the uncer-
tainty regarding the smoking-risk reduction after cessa-
tion. This offers the possibility to use standard statistical
packages and tools for analyses. In our data the uncer-
Excess riafter smoking-cessation according to linearly and e ponentially decreasing models (for the estimat d parame-ters  = 0.11 and  = 0.095)Figur  3
Excess risk after smoking-cessation according to line-
arly and exponentially decreasing models (for the 
estimated parameters = 0.11 and = 0.095). The 
excess-risk after smoking-cessation according to the linear 
and exponential deceasing models.
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tainty on the smoking-risk-reduction after cessation had
little effect on the estimates of the log-hazard ratio's of the
Cox model of smoking itself, and of other covariates in
the model, but this is probably due to the relatively large
sample size and event number in our sample. Finally, we
checked the proportional hazards assumption of the Cox
regression model with regard to smoking by extending the
model with the interaction of smoking and log(time), and
found little evidence for violation of this assumption (p =
0.88). This is somewhat surprising since the relative risk of
atherosclerotic events due to smoking is strongly related
to age ([20]), but this may be due to the somewhat
smaller age-distribution in our study.
In conclusion, smoking should be treated as a time-
dependent risk factor when using lifetime data. Moreover,
the risk reduction of smoking after cessation should be
taken into account.
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